Phase I/II trial evaluating toxicity and efficacy of adding stereotactic body radiotherapy to sorafenib in patients with metastatic, recurrent, or unresectable renal cell cancer.

Trial Profile

Phase I/II trial evaluating toxicity and efficacy of adding stereotactic body radiotherapy to sorafenib in patients with metastatic, recurrent, or unresectable renal cell cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2009

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SBRT-RCC
  • Most Recent Events

    • 17 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Actual patient number (1) added as reported by ClinicalTrials.gov.
    • 27 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top